BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 26345996)

  • 1. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
    Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
    Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
    Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
    J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.
    Lee BS; Kang S; Kim KA; Song YJ; Cheong KH; Cha HY; Kim CH
    Cell Death Dis; 2014 Apr; 5(4):e1159. PubMed ID: 24722284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.
    Zillhardt M; Christensen JG; Lengyel E
    Neoplasia; 2010 Jan; 12(1):1-10. PubMed ID: 20072648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.
    Lau PC; Wong EY
    Pathol Oncol Res; 2012 Apr; 18(2):357-63. PubMed ID: 21866424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells.
    Pei J; Chu T; Shao M; Teng J; Sha H; Gu A; Li R; Qian J; Mao W; Li Y; Han B
    Yonsei Med J; 2017 May; 58(3):581-591. PubMed ID: 28332364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.
    Li W; Li J; Wang Y; Zhang K; Li N; Tian Z; Ni B; Wang H; Ruan Z
    Oncotarget; 2016 Dec; 7(49):80586-80598. PubMed ID: 27811359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib Fails to Enhance the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Xenografts.
    Baschnagel AM; Galoforo S; Thibodeau BJ; Ahmed S; Nirmal S; Akervall J; Wilson GD
    Anticancer Res; 2015 Nov; 35(11):5973-82. PubMed ID: 26504020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered expression of E-cadherin by hepatocyte growth factor and effect on the prognosis of nasopharyngeal carcinoma.
    Xie LQ; Bian LJ; Li Z; Li Y; Li ZX; Li B
    Ann Surg Oncol; 2010 Jul; 17(7):1927-36. PubMed ID: 20131016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolfenamic Acid Inhibits the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma: Involvement of p38-Mediated Down-Regulation of Slug.
    Jittreetat T; Shin YS; Hwang HS; Lee BS; Kim YS; Sannikorn P; Kim CH
    Yonsei Med J; 2016 May; 57(3):588-98. PubMed ID: 26996556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
    Zhao L; Yasumoto K; Kawashima A; Nakagawa T; Takeuchi S; Yamada T; Matsumoto K; Yonekura K; Yoshie O; Yano S
    Cancer Sci; 2013 Dec; 104(12):1640-6. PubMed ID: 24118504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
    Zou HY; Li Q; Lee JH; Arango ME; McDonnell SR; Yamazaki S; Koudriakova TB; Alton G; Cui JJ; Kung PP; Nambu MD; Los G; Bender SL; Mroczkowski B; Christensen JG
    Cancer Res; 2007 May; 67(9):4408-17. PubMed ID: 17483355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis.
    Li N; Feng L; Han HQ; Yuan J; Qi XK; Lian YF; Kuang BH; Zhang YC; Deng CC; Zhang HJ; Yao YY; Xu M; He GP; Zhao BC; Gao L; Feng QS; Chen LZ; Yang L; Yang D; Zeng YX
    Cancer Lett; 2016 Oct; 381(1):14-22. PubMed ID: 27424523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model.
    Surriga O; Rajasekhar VK; Ambrosini G; Dogan Y; Huang R; Schwartz GK
    Mol Cancer Ther; 2013 Dec; 12(12):2817-26. PubMed ID: 24140933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET.
    Li YQ; Ren XY; He QM; Xu YF; Tang XR; Sun Y; Zeng MS; Kang TB; Liu N; Ma J
    Cell Death Dis; 2015 Jan; 6(1):e1618. PubMed ID: 25611392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.